Hey team,
Prior to OPTs August 2019 announcement, were patients that were the subject of the Phase 2 studies being treated through the Special Access Scheme and were prescribing doctors requesting their patients to remain on the product after the study finished (i.e. they they were already realising benefits which is why they requested this).
I am attemtping to draw some analogies between the sentiment and status quo just prior to OPTs result release announcement (what a glorious time it would have been) to DXBs current story.
Any direction greatly appreciated.
Cheers
Sand Stone
Hey team,Prior to OPTs August 2019 announcement, were patients...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.020(4.65%) |
Mkt cap ! $247.7M | |||
| Open | High | Low | Value | Volume |
| 42.5¢ | 46.3¢ | 42.5¢ | $1.449M | 3.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 143129 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 73280 | 3 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |